The Body Shot Bar voluntarily recalls Step 2 60 gold capsule due to undeclared Sibutramine

Silver Spring, MD, 2016-Jun-08 — /EPR Retail News/ — The Body Shot Bar is voluntarily recalling all lots distributed March 1- May 6 2016 of Step 2 60 gold capsule (350MG per) capsules to the consumer level. Step 2 has been found positive for Sibutramine after FDA sampling and testing.

Sibutramine is an appetite suppressant that was withdrawn from the U.S. market in October 2010. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. Phenolphthalein is an ingredient previously used in over-the-counter laxatives, but because of concerns of carcinogenicity, it is not currently approved for marketing in the United States. Health risks associated with phenolphthalein could include potentially serious gastrointestinal disturbances, irregular heartbeat, and cancer with long-term use. These undeclared ingredients make these products unapproved new drugs for which safety and efficacy have not been established. These products may also interact in life-threatening ways with other medications a consumer may be taking.

The Body Shot Bar has not received any complaints to date. The Body Shot Bar has not received any reports of adverse events related to this recall. 06/04/2016

The product is used as a weight loss dietary supplement and is packaged in a white bottle in blue and gold.  The affected Step 2 lots include the following expiration date 7/30/2017. Product was distributed nationwide to consumers via

The Body Shot Bar is notifying its customers by Email and is arranging for return. Consumers that have recalled Step 2 should stop using and discard.

Consumers with questions regarding this recall can contact The Body Shot Bar by phone (910)-849-3348 or on Monday thru Friday 10:00am to 5:30pm EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.




Tiffany Braswell